Tebbutt, N
159  results:
Search for persons X
?
2

ASCEND: a randomised, double-blinded, placebo-controlled, p..:

Lee, J. ; Dean, A. ; Price, T....
ESMO Gastrointestinal Oncology.  1 (2023)  - p. 3-8 , 2023
 
?
 
?
4

Prevalence of hypoxia and correlation with glycolytic metab..:

Lee, ST. ; Muralidharan, V. ; Tebbutt, N....
European Journal of Nuclear Medicine and Molecular Imaging.  48 (2020)  5 - p. 1585-1592 , 2020
 
?
5

Does Care for Australians With Pancreatic Cancer Compare Fa..:

Drosdowsky, A. ; Gough, K. ; Grewal, M....
Journal of Global Oncology.  4 (2018)  Supplement 2 - p. 82s-82s , 2018
 
?
 
?
10

6001 International randomised phase III study of capecitabi..:

Tebbutt, N. ; Gebski, V. ; Wilson, K....
European Journal of Cancer Supplements.  7 (2009)  2 - p. 321 , 2009
 
?
11

6539 The difference in standardized uptake value on 18F-FDG..:

Chionh, F. ; Handolias, D. ; Poon, A....
European Journal of Cancer Supplements.  7 (2009)  2 - p. 373 , 2009
 
?
13

Role of Low-dose, Noncontrast Computed Tomography from Inte..:

Lee, S. T. ; Tan, T. ; Poon, A. M. T....
Molecular Imaging and Biology.  10 (2007)  1 - p. 48-53 , 2007
 
?
14

285 Capecitabine and mitomycin C (MMC) is an active well-to..:

Rao, S. ; Cunningham, D. ; Hill, M.E....
European Journal of Cancer Supplements.  1 (2003)  5 - p. S87 , 2003
 
?
15

51 The value of routine serum carcino-embryonic antigen mea..:

Chau, I. ; Allen, M.J. ; Cunningham, D....
European Journal of Cancer Supplements.  1 (2003)  5 - p. S20 , 2003
 
1-15